Overview of long term care of breast cancer survivors.
Identifieur interne : 002670 ( PubMed/Corpus ); précédent : 002669; suivant : 002671Overview of long term care of breast cancer survivors.
Auteurs : Meagan E. Brennan ; Nehmat HoussamiSource :
- Maturitas [ 1873-4111 ] ; 2011.
English descriptors
- KwdEn :
- Antineoplastic Agents, Hormonal (adverse effects), Antineoplastic Agents, Hormonal (therapeutic use), Breast Neoplasms (diagnosis), Breast Neoplasms (drug therapy), Endometrial Neoplasms (etiology), Female, Holistic Health, Hot Flashes (etiology), Hot Flashes (therapy), Humans, Long-Term Care, Menopause, Premature, Survivors, Tamoxifen (adverse effects), Tamoxifen (therapeutic use), Vaginal Diseases (etiology), Vaginal Diseases (therapy).
- MESH :
- chemical , adverse effects : Antineoplastic Agents, Hormonal, Tamoxifen.
- chemical , therapeutic use : Antineoplastic Agents, Hormonal, Tamoxifen.
- diagnosis : Breast Neoplasms.
- drug therapy : Breast Neoplasms.
- etiology : Endometrial Neoplasms, Hot Flashes, Vaginal Diseases.
- therapy : Hot Flashes, Vaginal Diseases.
- Female, Holistic Health, Humans, Long-Term Care, Menopause, Premature, Survivors.
Abstract
Breast cancer, the most common cancer in women in developed countries, has a generally excellent prognosis, therefore long-term survivors living with the consequences of breast cancer ('survivors') and its treatment are an increasing group in clinical practice. This review discusses the complex issues relevant to survivorship care, including current recommendations for ongoing adjuvant hormonal therapy (tamoxifen and aromatase inhibitors), and the management of side effects of cancer treatment (such as menopause, arthralgia, and lymphoedema). Annual mammography screening is advised for detection of second breast cancers, and symptom-directed assessment is warranted where there is suspicion of distant recurrence or (in women using tamoxifen) of endometrial cancer. Management of menopausal symptoms, including treatment-induced premature menopause, is a key issue for many survivors, and can be challenging to manage as conventional hormone replacement therapy is contraindicated in most of these women. Specific therapeutic options for hot flushes and vaginal symptoms are discussed. The review also emphasises the need for survivorship care to include optimisation of general health, including psychosocial and sexual health, bone health and the evaluation of lifestyle-related risk factors and genetic factors. The review provides guidance on the management of many of these issues, and highlights areas requiring further evidence and research.
DOI: 10.1016/j.maturitas.2011.03.010
PubMed: 21489727
Links to Exploration step
pubmed:21489727Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Overview of long term care of breast cancer survivors.</title><author><name sortKey="Brennan, Meagan E" sort="Brennan, Meagan E" uniqKey="Brennan M" first="Meagan E" last="Brennan">Meagan E. Brennan</name><affiliation><nlm:affiliation>Screening and Test Evaluation Program (STEP), School of Public Health, Sydney Medical School, University of Sydney, Camperdown, Sydney, NSW, Australia. meagan.brennan@sydney.edu.au</nlm:affiliation></affiliation></author><author><name sortKey="Houssami, Nehmat" sort="Houssami, Nehmat" uniqKey="Houssami N" first="Nehmat" last="Houssami">Nehmat Houssami</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21489727</idno><idno type="pmid">21489727</idno><idno type="doi">10.1016/j.maturitas.2011.03.010</idno><idno type="wicri:Area/PubMed/Corpus">002670</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002670</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Overview of long term care of breast cancer survivors.</title><author><name sortKey="Brennan, Meagan E" sort="Brennan, Meagan E" uniqKey="Brennan M" first="Meagan E" last="Brennan">Meagan E. Brennan</name><affiliation><nlm:affiliation>Screening and Test Evaluation Program (STEP), School of Public Health, Sydney Medical School, University of Sydney, Camperdown, Sydney, NSW, Australia. meagan.brennan@sydney.edu.au</nlm:affiliation></affiliation></author><author><name sortKey="Houssami, Nehmat" sort="Houssami, Nehmat" uniqKey="Houssami N" first="Nehmat" last="Houssami">Nehmat Houssami</name></author></analytic><series><title level="j">Maturitas</title><idno type="eISSN">1873-4111</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents, Hormonal (adverse effects)</term><term>Antineoplastic Agents, Hormonal (therapeutic use)</term><term>Breast Neoplasms (diagnosis)</term><term>Breast Neoplasms (drug therapy)</term><term>Endometrial Neoplasms (etiology)</term><term>Female</term><term>Holistic Health</term><term>Hot Flashes (etiology)</term><term>Hot Flashes (therapy)</term><term>Humans</term><term>Long-Term Care</term><term>Menopause, Premature</term><term>Survivors</term><term>Tamoxifen (adverse effects)</term><term>Tamoxifen (therapeutic use)</term><term>Vaginal Diseases (etiology)</term><term>Vaginal Diseases (therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Agents, Hormonal</term><term>Tamoxifen</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents, Hormonal</term><term>Tamoxifen</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Endometrial Neoplasms</term><term>Hot Flashes</term><term>Vaginal Diseases</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Hot Flashes</term><term>Vaginal Diseases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Holistic Health</term><term>Humans</term><term>Long-Term Care</term><term>Menopause, Premature</term><term>Survivors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Breast cancer, the most common cancer in women in developed countries, has a generally excellent prognosis, therefore long-term survivors living with the consequences of breast cancer ('survivors') and its treatment are an increasing group in clinical practice. This review discusses the complex issues relevant to survivorship care, including current recommendations for ongoing adjuvant hormonal therapy (tamoxifen and aromatase inhibitors), and the management of side effects of cancer treatment (such as menopause, arthralgia, and lymphoedema). Annual mammography screening is advised for detection of second breast cancers, and symptom-directed assessment is warranted where there is suspicion of distant recurrence or (in women using tamoxifen) of endometrial cancer. Management of menopausal symptoms, including treatment-induced premature menopause, is a key issue for many survivors, and can be challenging to manage as conventional hormone replacement therapy is contraindicated in most of these women. Specific therapeutic options for hot flushes and vaginal symptoms are discussed. The review also emphasises the need for survivorship care to include optimisation of general health, including psychosocial and sexual health, bone health and the evaluation of lifestyle-related risk factors and genetic factors. The review provides guidance on the management of many of these issues, and highlights areas requiring further evidence and research.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21489727</PMID><DateCreated><Year>2011</Year><Month>05</Month><Day>16</Day></DateCreated><DateCompleted><Year>2011</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-4111</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Maturitas</Title><ISOAbbreviation>Maturitas</ISOAbbreviation></Journal><ArticleTitle>Overview of long term care of breast cancer survivors.</ArticleTitle><Pagination><MedlinePgn>106-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.maturitas.2011.03.010</ELocationID><Abstract><AbstractText>Breast cancer, the most common cancer in women in developed countries, has a generally excellent prognosis, therefore long-term survivors living with the consequences of breast cancer ('survivors') and its treatment are an increasing group in clinical practice. This review discusses the complex issues relevant to survivorship care, including current recommendations for ongoing adjuvant hormonal therapy (tamoxifen and aromatase inhibitors), and the management of side effects of cancer treatment (such as menopause, arthralgia, and lymphoedema). Annual mammography screening is advised for detection of second breast cancers, and symptom-directed assessment is warranted where there is suspicion of distant recurrence or (in women using tamoxifen) of endometrial cancer. Management of menopausal symptoms, including treatment-induced premature menopause, is a key issue for many survivors, and can be challenging to manage as conventional hormone replacement therapy is contraindicated in most of these women. Specific therapeutic options for hot flushes and vaginal symptoms are discussed. The review also emphasises the need for survivorship care to include optimisation of general health, including psychosocial and sexual health, bone health and the evaluation of lifestyle-related risk factors and genetic factors. The review provides guidance on the management of many of these issues, and highlights areas requiring further evidence and research.</AbstractText><CopyrightInformation>Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brennan</LastName><ForeName>Meagan E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Screening and Test Evaluation Program (STEP), School of Public Health, Sydney Medical School, University of Sydney, Camperdown, Sydney, NSW, Australia. meagan.brennan@sydney.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houssami</LastName><ForeName>Nehmat</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Maturitas</MedlineTA><NlmUniqueID>7807333</NlmUniqueID><ISSNLinking>0378-5122</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>094ZI81Y45</RegistryNumber><NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018931" MajorTopicYN="N">Antineoplastic Agents, Hormonal</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016889" MajorTopicYN="N">Endometrial Neoplasms</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006694" MajorTopicYN="N">Holistic Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019584" MajorTopicYN="N">Hot Flashes</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008594" MajorTopicYN="N">Menopause, Premature</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017741" MajorTopicYN="Y">Survivors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013629" MajorTopicYN="N">Tamoxifen</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014623" MajorTopicYN="N">Vaginal Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>02</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>03</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>03</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21489727</ArticleId><ArticleId IdType="pii">S0378-5122(11)00092-2</ArticleId><ArticleId IdType="doi">10.1016/j.maturitas.2011.03.010</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002670 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002670 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:21489727
|texte= Overview of long term care of breast cancer survivors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:21489727" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |